Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers

ConclusionThis study identified circulating HGF and several inflammatory and angiogenic proteins as prognostic biomarkers. Furthermore,MET amplification status is associated with both baseline expression and on-treatment modulation of members of angiogenesis and TGF- β pathway proteins.Clinical trials registration numberClinicalTrials.gov identifier: NCT02008383.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research